Abstract:Objectives The aim of the study was to assess the effect of gemicitabine by transcatheter arterial infusion on pancreatic cancer. Methods Twenty patients with advanced pancreatic cancer were given gemicitabine (1 000mg/m2)by arterial and intravenous infusion and other 9 patients treated with 5-fluorouracil (1 000 mg), adriamycin (40 ?50 mg), carboplatin (200 mg) by arterial infusion were used as control. Pain relief, improvement of Karnofsky score, efficacy and side effects of both groups were evaluated. Results Pain relief rate was 75% in gemicitabine group and 44. 4% in control group; there was no significant difference between two groups. The Karnofsky score got better in 60% patients of gemicitabine group, and in 44. 4% patients of control group. The partial remission (PD) rate was 30% in gemicitabine group, and 22. 2% in control group. The one-year and 6-month survival rates were 25% and 85% respectively in gemicitabine group, and 0 and 66. 7% in control group. The mean survival time was 9 months in gemicitabine group and 7. 9 months in control group. Toxicity was low and well tolerated in both groups. Conclusions Transcatheter arterial infusion of gemicitabine relieved pain and improved Karnofsky score and prolonged lifetime of patients with advanced pancreatic cancer. There were no severe side effects.

Transcatheter Arterial Infusion of Gemicitabine for Treatment of Advanced Pancreatic Cancer